GeneDx (NASDAQ:WGS) CEO Katherine Stueland Sells 17,179 Shares

GeneDx Holdings Corp. (NASDAQ:WGS) CEO Katherine Stueland sold 17,179 shares of GeneDx stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $76.80, for a total value of $1,319,347.20. Following the completion of the transaction, the chief executive officer owned 58,447 shares of the company’s stock, valued at approximately $4,488,729.60. This trade represents a 22.72% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Katherine Stueland also recently made the following trade(s):

• On Wednesday, March 4th, Katherine Stueland sold 25,459 shares of GeneDx stock. The shares were sold at an average price of $78.61, for a total value of $2,001,331.99.
• On Thursday, January 29th, Katherine Stueland sold 1,653 shares of GeneDx stock. The stock was sold at an average price of $94.00, for a total value of $155,382.00.

GeneDx Trading Down 0.8%

WGS stock traded down $0.61 during mid-day trading on Tuesday, reaching $75.50. 622,092 shares of the stock traded hands, compared to its average volume of 799,978. GeneDx Holdings Corp. has a one year low of $55.17 and a one year high of $170.87. The stock has a market capitalization of $2.21 billion, a PE ratio of 53.98 and a beta of 2.03. The company has a debt-to-equity ratio of 0.16, a quick ratio of 2.34 and a current ratio of 2.46. The business has a 50-day moving average price of $95.16 and a two-hundred day moving average price of $120.38.

GeneDx (NASDAQ:WGS) last released its earnings results on Monday, February 23rd. The company reported $0.14 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.11 by $0.03. GeneDx had a negative net margin of 4.92% and a positive return on equity of 14.73%. The firm had revenue of $120.99 million during the quarter, compared to analyst estimates of $120.80 million. Equities research analysts expect that GeneDx Holdings Corp. will post 0.97 EPS for the current year.

Institutional Trading of GeneDx

Large investors have recently modified their holdings of the company. Jones Financial Companies Lllp grew its stake in GeneDx by 664.3% in the third quarter. Jones Financial Companies Lllp now owns 214 shares of the company’s stock worth $25,000 after purchasing an additional 186 shares in the last quarter. Kestra Advisory Services LLC bought a new stake in GeneDx during the 4th quarter valued at $27,000. Quarry LP raised its position in GeneDx by 248.8% during the 3rd quarter. Quarry LP now owns 293 shares of the company’s stock valued at $32,000 after purchasing an additional 209 shares in the last quarter. Ramirez Asset Management Inc. purchased a new stake in shares of GeneDx in the 4th quarter worth $33,000. Finally, Greenline Wealth Management LLC purchased a new stake in shares of GeneDx in the 4th quarter worth $33,000. Hedge funds and other institutional investors own 61.72% of the company’s stock.

Wall Street Analyst Weigh In

A number of research firms have recently commented on WGS. Weiss Ratings reaffirmed a “sell (d)” rating on shares of GeneDx in a research note on Wednesday, January 21st. Zacks Research raised GeneDx from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, February 25th. BTIG Research cut their price objective on GeneDx from $200.00 to $170.00 and set a “buy” rating on the stock in a research report on Tuesday, February 24th. Piper Sandler reiterated an “overweight” rating and issued a $130.00 target price (down from $160.00) on shares of GeneDx in a research note on Tuesday, February 24th. Finally, Canaccord Genuity Group lifted their target price on GeneDx from $160.00 to $170.00 and gave the stock a “buy” rating in a research report on Monday, December 22nd. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $150.71.

About GeneDx

GeneDx is a clinical diagnostics company specializing in comprehensive genetic and genomic testing for rare and inherited disorders. The company offers a broad portfolio of assays, including targeted gene panels, whole exome sequencing, whole genome sequencing and chromosomal microarray analysis. GeneDx’s laboratory services support the diagnosis of a wide range of conditions—from rare pediatric diseases and hereditary cancer syndromes to neuromuscular and metabolic disorders—by providing clinicians with detailed variant interpretation and reporting.

Founded in 2000 and based in Gaithersburg, Maryland, GeneDx was established with the aim of accelerating the translation of genomic discoveries into clinical care.